Sana Biotechnology

### Executive Summary Sana Biotechnology raised $367.4M in a private placement (Regulation D) for synthetic biology and intracellular mRNA delivery, with first sale on 2025-10-12. The involvement of Lockheed Martin Ventures and Bessemer Venture Partners as related persons signals strong strategic and institutional backing. This is a Form D initial notice, not an amendment, indicating fresh capital deployment. ### Investor Edge Watch for subsequent Form D/A amendments to see if capital increases or terms change, and monitor Lockheed Martin for any related press releases or contract awards that could validate the technology's dual-use potential. ### Sector capital positioning This large raise in synthetic biology and mRNA delivery underscores continued institutional appetite for next-generation biotech platforms, particularly those with dual-use potential (defense/health). The $367.4M amount is substantial for a private placement, suggesting high confidence in the technology's scalability. ### Convergence Signals No explicit public signals (patents, contracts, legislation) are evident from the filing. However, Lockheed Martin Ventures' involvement hints at potential defense or aerospace applications for intracellular delivery, which could align with government biodefense or space biology initiatives. ### Key Takeaways - Sana Biotechnology raised $367.4M in a private placement for synthetic biology and intracellular mRNA delivery. - Lockheed Martin Ventures and Bessemer Venture Partners are listed as related persons, indicating strategic and institutional backing. - The filing is a Form D initial notice, not an amendment, suggesting fresh capital raise with potential for future amendments. ### Risk Indicators & Flags No red flags in the filing itself (Form D initial notice, no amendments). However, the large amount for a private company in a speculative sector (synthetic biology) carries execution risk. Regulatory concerns around mRNA delivery and intracellular therapies are inherent but not flagged in the filing. ### Verification & References Filing is a Form D (initial notice) with SEC accession 0001702600-24-20151, first sale date 2025-10-12, and total offering amount $367.4M. Related persons include Lockheed Martin Ventures and Bessemer Venture Partners. Verify at SEC EDGAR: https://www.sec.gov/cgi-bin/browse-edgar?company=Sana%20Biotechnology&type=D&action=getcompany